Sanofi-Aventis S.A. ADR (SNY)
$56.21
0.98 (1.77%)
SNY Stock Quote Delayed 30 Minutes
It May Be Time to Trim Away at Your Portfolio
The stock market is doing well for October, but its may be time to look through your portfolio in order to trim away some of the upcoming losers
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
70.30B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2.18M
Day's Range
$55.56 - $56.32
52-Week Range
$42.63 - $56.32
Dividend & Yield
$1.90 (3.39%)
SNY Stock Predictions, Articles, and Sanofi-Aventis S.A. ADR News
5 Large-Cap Growth Stocks That Aren’t Done
Most people associate small-cap stocks with growth, not large caps -- but these high-worth companies have pretty impressive earnings upside themselves.
It’s Hard to Win the Pharma News Game
Big news for three cancer-treatment drugs had virtually zero effect on the stocks. Here's why investors shouldn't have been surprised, and what they can learn.
2 Stocks to Buy, 2 to Sell in Big Pharma
Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries.
Bulls vs. Bears: Can Biogen Keep Booming?
Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments.
Intimidated By Your New 401k? Try a Target-Date Fund
Signing up for a 401k is cake, but deciding how to allocate your funds isn't so easy. Target-date mutual funds can shoulder that burden.
The Best and Worst Mutual Funds of Q1 2013
Healthcare and Japanese stocks were among some of the hottest mutual fund flavors of the year's first quarter, while India and gold lagged behind.
Winners After Novo Nordisk’s Insulin Rejection
Eli Lilly and Sanofi look like the biggest players that are best suited to benefit from Novo Nordisk's diabetes-drug setback, but a smaller player could emerge, too.
Little News, Little Wiggle — Monday’s IP Market Recap
A slow Monday featured a lack of economic or earnings news and led investors to mostly sit on the sidelines for the day.
Flu’s Pain Is All Gain for These Companies
As this year's flu season intensifies, so do the profits for some businesses such as vaccine makers, pharmacies and even certain food and beverage makers.
Flu Season: Where Investors Can Find Relief
This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them.
Big Pharma: 2012-13’s Flu Vaccine Field
Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season.
Biotech Movers: Regeneron Pops, 3 Flop
While Regeneron soared on behind its macular degeneration treatment, Dynavax, Navidea and AspenBio suffered serious setbacks.
China’s Diabetes Epidemic Boosts Big Pharma
The world's largest population of diabetics is growing alarmingly, and combating it raises the prospects for names like Merck, Novo Nordisk and Sanofi.
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why.
Investors Who Own Japanese Stocks About to Get a Surprise
The China-Japan trade relationship in on a rocky road due to the Senkaku/Daiouy Islands dispute, and the problems extend to U.S. investors in Japanese stocks
Should I Buy Abbott Labs? 3 Pros, 3 Cons
Success in a drug regimen meant to treat hepatitis C is buoying shares of Abbott Laboratories, but has the easy money in ABT shares already been made?
6 Pharmaceutical Stocks to Buy Now
The grades of six Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
A Healthy Portfolio Is Heavy in Health Care
Investors would be foolish to ignore the massive demographic shift and growth potential that is boosting health care stocks right now.
5 Tempting French Dividend Stocks
France boasts the second-largest economy in the eurozone, making these five high-yielding picks great plays on the region.
7 Pharmaceutical Stocks to Buy Now
The grades of seven Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").
